Thai Nakarin Hospital Public Company Limited and its subsidiary Review report interim financial information For the three-month and nine-month periods ended 30 April 2024 Independent Auditor's Report on Review of Interim Financial Information

To the Shareholders of Thai Nakarin Hospital Public Company Limited

I have reviewed the accompanying consolidated statement of financial position of Thai Nakarin Hospital Public Company Limited and its subsidiary ("the Group") as at 30 April 2024, and the related consolidated statements of comprehensive income, changes in shareholders' equity and cash flows for the three-month and nine-month periods then ended, as well as the condensed notes to the interim consolidated financial statements. I have also reviewed the separate financial information of Thai Nakarin Hospital Public Company Limited for the same period (collectively "interim financial information"). Management is responsible for the preparation and presentation of this interim financial information in accordance with Thai Accounting Standard 34 Interim Financial Reporting. My responsibility is to express a conclusion on this interim financial information based on my review.

Scope of review

I conducted my review in accordance with Thai Standard on Review Engagements 2410, Review of Interim Financial Information Performed by the Independent Auditor of the Entity. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Thai Standards on Auditing and consequently does not enable me to obtain assurance that I would become aware of all significant matters that might be identified in an audit. Accordingly, I do not express an audit opinion.

Conclusion

Based on my review, nothing has come to my attention that causes me to believe that the accompanying interim financial information is not prepared, in all material respects, in accordance with Thai Accounting Standard 34 Interim Financial Reporting.

Samran Taengcham
Certified Public Accountant (Thailand) No. 8021

EY Office Limited

Bangkok: 12 June 2024

Statement of financial position

As at 30 April 2024

(Unit: Thousand Baht)

		Consolidated financial statements		Separate financial statements		
		30 April	31 July	30 April	31 July	
	Note	2024	2023	2024	2023	
		(Unaudited	(Audited)	(Unaudited	(Audited)	
		but reviewed)		but reviewed)		
Assets						
Current assets						
Cash and cash equivalents	3	1,338,978	1,297,934	1,337,397	1,296,171	
Trade and other receivables	2, 4	214,132	211,890	213,949	211,709	
Inventories		38,913	33,575	38,913	33,575	
Other current financial assets	5	271,508	140,000	271,508	140,000	
Other current assets		203	263	203	263	
Total current assets		1,863,734	1,683,662	1,861,970	1,681,718	
Non-current assets						
Investment in subsidiary	6	-	-	1,000	1,000	
Property, plant and equipment	7	944,894	894,272	944,860	894,272	
Intangible assets		9,322	10,402	9,322	10,402	
Right-of-use assets	8	552,750	569,657	552,750	569,657	
Deferred tax assets		25,718	23,020	25,718	23,020	
Other non-current assets		133	133	133	133	
Total non-current assets		1,532,817	1,497,484	1,533,783	1,498,484	
Total assets		3,396,551	3,181,146	3,395,753	3,180,202	

Thai Nakarin Hospital Public Company Limited and its subsidiary Statement of financial position (continued)

As at 30 April 2024

(Unit: Thousand Baht)

		Consolidated financial statements		Separate financial statements		
		30 April	31 July	30 April	31 July	
	Note	2024	2023	2024	2023	
		(Unaudited	(Audited)	(Unaudited	(Audited)	
		but reviewed)		but reviewed)		
Liabilities and shareholders' equity						
Current liabilities						
Trade and other payables	9	180,935	185,074	180,810	184,924	
Doctor fee payable		101,901	94,800	101,901	94,800	
Income tax payable		15,013	29,023	15,013	29,023	
Other current liabilities		29,805	33,242	29,805	33,242	
Total current liabilities		327,654	342,139	327,529	341,989	
Non-current liabilities						
Provision for long-term employee benefits		108,464	98,934	108,464	98,934	
Other non-current financial liabilities		5,945	5,440	5,945	5,440	
Total non-current liabilities		114,409	104,374	114,409	104,374	
Total liabilities		442,063	446,513	441,938	446,363	
Shareholders' equity						
Share capital						
Registered						
180,000,000 ordinary shares of Baht 1	each	180,000	180,000	180,000	180,000	
Issued and fully paid-up						
180,000,000 ordinary shares of Baht 1	each	180,000	180,000	180,000	180,000	
Share premium		20,538	20,538	20,538	20,538	
Retained earnings						
Appropriated - statutory reserve		18,000	18,000	18,000	18,000	
Unappropriated		2,735,950	2,516,095	2,735,277	2,515,301	
Equity attibutable to owners of the com	pany	2,954,488	2,734,633	2,953,815	2,733,839	
Total liabilities and shareholders' equity	y	3,396,551	3,181,146	3,395,753	3,180,202	

The accompanying notes are an integral part of the financial statements.	

		Directors

Statement of comprehensive income

For the three-month period ended 30 April 2024

(Unit: Thousand Baht except earnings per share expressed in Baht)

		Consolidated financial statements		Separate financial statements		
		30 April	30 April	30 April	30 April	
	Note	2024	2023	2024	2023	
Profit and loss:						
Revenues						
Revenues from hospital operations		639,011	583,624	639,011	583,624	
Other income		3,236	2,219	3,236	2,229	
Total revenues		642,247	585,843	642,247	585,853	
Expenses						
Cost of hospital operations and goods sold		472,390	429,695	472,390	429,695	
Administrative expenses		64,800	62,124	64,751	62,086	
Total expenses		537,190	491,819	537,141	491,781	
Operating profit		105,057	94,024	105,106	94,072	
Finance income		4,815	2,199	4,815	2,198	
Profit before income tax expenses		109,872	96,223	109,921	96,270	
Income tax expenses	10	(20,903)	(18,235)	(20,903)	(18,234)	
Profit for the period		88,969	77,988	89,018	78,036	
Other comprehensive income:						
Other comprehensive income for the period			<u> </u>	<u> </u>		
Total comprehensive income for the period		88,969	77,988	89,018	78,036	
Basic earnings per share						
Profit (Baht)		0.49	0.43	0.49	0.43	
Weighted average number of ordinary shares						
(Thousand shares)		180,000	180,000	180,000	180,000	

Statement of comprehensive income

For the nine-month period ended 30 April 2024

(Unit: Thousand Baht except earnings per share expressed in Baht)

		Consolidated financial statements		Separate financial statements	
		30 April	30 April	30 April	30 April
	<u>Note</u>	2024	2023	2024	2023
Profit and loss:					
Revenues					
Revenues from hospital operations		2,005,715	1,774,086	2,005,715	1,774,086
Other income		7,180	9,885	7,180	9,122
Total revenues		2,012,895	1,783,971	2,012,895	1,783,208
Expenses					
Cost of hospital operations and goods sold		1,431,987	1,305,689	1,431,987	1,305,343
Administrative expenses		189,043	189,361	188,917	189,246
Total expenses		1,621,030	1,495,050	1,620,904	1,494,589
Operating profit		391,865	288,921	391,991	288,619
Finance income		14,072	6,048	14,067	6,045
Profit before income tax expenses		405,937	294,969	406,058	294,664
Income tax expenses	10	(78,082)	(55,938)	(78,082)	(55,929)
Profit for the period		327,855	239,031	327,976	238,735
Other comprehensive income:					
Other comprehensive income for the period			<u> </u>		
Total comprehensive income for the period		327,855	239,031	327,976	238,735
Basic earnings per share					
Profit (Baht)		1.82	1.33	1.82	1.33
Weighted average number of ordinary shares					
(Thousand shares)		180,000	180,000	180,000	180,000

(Unaudited but reviewed)

Thai Nakarin Hospital Public Company Limited and its subsidiary

Statement of changes in shareholders' equity

For the nine-month period ended 30 April 2024

(Unit: Thousand Baht)

	Consolidated financial statements					
	Issued and		Retained	Total		
	paid-up		Appropriated -		shareholders'	
	share capital	Share premium	statutory reserve	Unappropriated	equity	
Balance as at 1 August 2022	180,000	20,538	18,000	2,265,462	2,484,000	
Total comprehensive income for the period	-	-	-	239,031	239,031	
Dividend paid (Note 11)				(108,000)	(108,000)	
Balance as at 30 April 2023	180,000	20,538	18,000	2,396,493	2,615,031	
Balance as at 1 August 2023	180,000	20,538	18,000	2,516,095	2,734,633	
Total comprehensive income for the period	-	-	-	327,855	327,855	
Dividend paid (Note 11)				(108,000)	(108,000)	
Balance as at 30 April 2024	180,000	20,538	18,000	2,735,950	2,954,488	

(Unaudited but reviewed)

Thai Nakarin Hospital Public Company Limited and its subsidiary

Statement of changes in shareholders' equity

For the nine-month period ended 30 April 2024

(Unit: Thousand Baht)

	Separate financial statements					
	Issued and		Retained	Total		
	paid-up		Appropriated -		shareholders'	
	share capital	Share premium	statutory reserve	Unappropriated	equity	
Balance as at 1 August 2022	180,000	20,538	18,000	2,264,940	2,483,478	
Total comprehensive income for the period	-	-	-	238,735	238,735	
Dividend paid (Note 11)				(108,000)	(108,000)	
Balance as at 30 April 2023	180,000	20,538	18,000	2,395,675	2,614,213	
Balance as at 1 August 2023	180,000	20,538	18,000	2,515,301	2,733,839	
Total comprehensive income for the period	-	-	-	327,976	327,976	
Dividend paid (Note 11)				(108,000)	(108,000)	
Balance as at 30 April 2024	180,000	20,538	18,000	2,735,277	2,953,815	

Thai Nakarin Hospital Public Company Limited and its subsidiary Statement of cash flows

For the nine-month period ended 30 April 2024

(Unit: Thousand Baht)

	Consolidated finan	cial statements	Separate financial statements	
	30 April	30 April	30 April	30 April
	2024	2023	2024	2023
Cash flows from operating activities				
Profit before tax	405,937	294,969	406,058	294,664
Adjustments to reconcile profit before tax to				
net cash provided by (paid from) operating activities:				
Depreciation and amortisation expenses	91,495	85,902	91,495	85,902
Allowance for expected credit losses	4,186	12,669	4,186	12,669
Long-term employee benefit expenses	11,025	10,442	11,025	10,442
Gain on disposals of equipment	-	(1,742)	-	(1,742)
Interest income	(14,072)	(6,048)	(14,067)	(6,045)
Profit from operating activities before changes				
in operating assets and liabilities	498,571	396,192	498,697	395,890
Decrease (increase) in operating assets				
Trade and other receivables	(5,302)	132,429	(5,300)	132,430
Inventories	(5,338)	(1,978)	(5,338)	(1,978)
Other current assets	60	986	60	986
Other non-current assets	-	(47)	-	(47)
Increase (decrease) in operating liabilities				
Trade and other payables	6,781	(8,212)	6,806	(7,294)
Doctor fee payable	7,101	(9,603)	7,101	(9,603)
Other current liabilities	(3,437)	2,600	(3,437)	2,600
Provision for long-term employee benefits	(1,495)	(6,391)	(1,495)	(6,391)
Other non-current financial liabilities	505	(4,404)	505	(4,404)
Cash from operating activities	497,446	501,572	497,599	502,189
Cash paid for income tax	(94,790)	(75,027)	(94,790)	(74,927)
Net cash from operating activities	402,656	426,545	402,809	427,262

Statement of cash flows (continued)

For the nine-month period ended 30 April 2024

(Unit: Thousand Baht)

	Consolidated financial statements		Separate financial statements	
	30 April	30 April	30 April	30 April
	2024	2023	2024	2023
Cash flows from investing activities				
Interest received	12,946	5,510	12,941	5,507
Decrease in other current financial assets	(131,508)	302,052	(131,508)	302,052
Cash paid for purchases of building improvement and equipment	(135,403)	(196,699)	(135,369)	(196,699)
Cash paid for purchase of intangible assets	(47)	(1,422)	(47)	(1,422)
Cash received from disposals of equipment	400	2,824	400	2,824
Net cash from (used in) investing activities	(253,612)	112,265	(253,583)	112,262
Cash flows from financing activities				
Dividend paid	(108,000)	(108,000)	(108,000)	(108,000)
Net cash used in financing activities	(108,000)	(108,000)	(108,000)	(108,000)
Net increase in cash and cash equivalents	41,044	430,810	41,226	431,524
Cash and cash equivalents at beginning of period	1,297,934	699,568	1,296,171	697,019
Cash and cash equivalents at end of period (Note 3)	1,338,978	1,130,378	1,337,397	1,128,543
Supplemental cash flows information				
Non-cash items				
Accounts payable - construction and equipment purchase	16,290	45,934	16,290	45,934

Thai Nakarin Hospital Public Company Limited and its subsidiary Notes to consolidated interim financial statements

For the three-month and nine-month periods ended 30 April 2024

1. General information

1.1 Corporate information

Thai Nakarin Hospital Public Company Limited ("the Company") is a public company incorporated and domiciled in Thailand. The Company is principally engaged in hospital business. It registered address is as follows:

Head office is located at No. 345 Thepparat Road, Bangna Nuea, Bangna, Bangkok.

Branch offices is located at No. 107/1 Moo 7 Siri Sothon Road, Bang Phra, Mueang Chachoengsao, Chachoengsao.

1.2 Basis for the preparation of interim financial statements

These interim financial statements are prepared in accordance with Thai Accounting Standard No. 34 Interim Financial Reporting, with the Company choosing to present condensed interim financial statements. However, the Company has presented the statements of financial position, comprehensive income, changes in shareholders' equity, and cash flows in the same format as that used for the annual financial statements.

The interim financial statements are intended to provide information additional to that included in the latest annual financial statements. Accordingly, they focus on new activities, events and circumstances so as not to duplicate information previously reported. These interim financial statements should therefore be read in conjunction with the latest annual financial statements.

The interim financial statements in Thai language are the official statutory financial statements of the Company. The interim financial statements in English language have been translated from the Thai language financial statements.

1.3 Basis of consolidation

These interim consolidated financial statements include the financial statements of Thai Nakarin Hospital Public Company Limited and its subsidiary ("the Group") and have been prepared on the same basis as that applied for the consolidated financial statements for the year ended 31 July 2023. There have been no changes in the structure of the subsidiary during the current period.

1.4 Significant accounting policies

The interim financial statements are prepared using the same accounting policies and methods of computation as were used for the financial statements for the year ended 31 July 2023.

Financial reporting standards that became effective in the current year

The revised financial reporting standards which are effective for fiscal years beginning on or after 1 January 2023, do not have any significant impact on the Group's financial statements.

<u>Financial reporting standards that will become effective for fiscal years beginning on or after</u>

1 January 2024

The Federation of Accounting Professions issued a number of revised financial reporting standards and interpretations, which are effective for fiscal years beginning on or after 1 January 2024. The management of the Group is currently evaluating the impact of these standards to the financial statements in the years when they are adopted.

2. Related party transactions

During the periods, the Company had significant business transactions with related parties. Such transactions, which are summarised below, arose in the ordinary course of business and were concluded on commercial terms and bases agreed upon between the Company and those related parties.

Transfer pricing policy

examinations conducted on other premises and

special equipment charges

Revenue from hospital operations	Based on the price charged to normal customers
Rental income	Rates as stipulated in the agreements
Purchase fixed assets	Rates as stipulated in the agreements
Doctor fee expenses (directors and	Paid at the same rate as other doctors in the hospital
management)	
Medical welfare	Under the Company's regulations, medical welfare
	benefits are granted to directors, their spouses,
	children and parents, up to a specified amount
	per annum. These benefits exclude doctor fees,

(Unit: Thousand Baht)
For three-month periods ended 30 April

_	<u></u>					
	Consol	idated	Separate			
_	financial st	atements	financial statements			
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>		
Transactions with related companies						
and persons						
Revenue from hospital operations	3	-	3	-		
Purchase fixed assets	-	16,100	-	16,100		
Doctor fee expenses						
(directors and management)	1,254	2,869	1,254	2,869		
Medical welfare	1,118	1,094	1,118	1,094		

(Unit: Thousand Baht)

	For nine-month periods ended 30 April				
-	Consol	idated	Separate		
	financial st	financial statements		financial statements	
	<u>2024</u>	<u>2023</u>	<u>2024</u>	2023	
Transactions with related companies					
and persons					
Revenue from hospital operations	45	55	45	55	
Purchase fixed assets	-	16,100	-	16,100	
Doctor fee expenses					
(directors and management)	3,924	7,763	3,924	7,763	
Medical welfare	3.447	3.432	3.447	3.432	

The balances of accounts as at 30 April 2024 and 31 July 2023 between the Company and its related parties are as follows:

			(Unit: The	ousand Baht)
	Consol	idated	Separate	
	financial st	atements	financial st	atements
	30 April	31 July	30 April	31 July
	2024	2023	2024	2023
Trade receivables - related parties				
(Note 4)				
Related companies (related by common				
shareholders and directors)	3	23	3	23
Total trade receivables - related parties	3	23	3	23

			(Unit: The	ousand Baht)	
	Consolidated		Sepa	Separate	
	financial st	financial statements		atements	
	30 April	31 July	30 April	31 July	
	2024	2023	2024	2023	
Doctor fee payable - related persons					
Related persons (directors and management)	397	475	397	475	
Total doctor fee payable - related persons	397	475	397	475	

Directors and management's benefits

During the three-month and nine-month periods ended 30 April 2024 and 2023, the Company had employee benefit expenses to its directors and management as below.

			(Unit: Tho	ousand Baht)	
	For three-mo	For three-month periods		For nine-month periods	
	ended 3	ended 30 April		ended 30 April	
	<u>2024</u>	2023	<u>2024</u>	<u>2023</u>	
Short-term employee benefits	10,605	12,771	30,316	36,440	
Post-employment benefits	942	626	2,804	1,887	
Total	11,547	13,397	33,120	38,327	

3. Cash and cash equivalents

	(Unit: Thousand Bal			
	Consolidated		Sepa	arate
	financial s	financial statements		tatements
	30 April	31 July	30 April	31 July
	2024	2023	2024	2023
Cash	6,782	5,301	6,778	5,301
Bank deposits	1,332,196	1,292,633	1,330,619	1,290,870
Total cash and cash equivalents	1,338,978	1,297,934	1,337,397	1,296,171

As at 30 April 2024, bank deposits in savings accounts carried interests between 0.15 and 1.40 percent per annum (31 July 2023: between 0.15 and 1.25 percent per annum).

4. Trade and other receivables

	Consolidated financial statements		Separate	Unit: Thousand Baht) eparate financial statements	
	30 April	31 July	30 April	31 July	
	2024	2023	2024	2023	
Trade receivables - related parties					
Aged on the basis of due dates					
Not due yet	-	10	-	10	
Past due					
Up to 3 months	1	4	1	4	
3 - 6 months	2	-	2	-	
6 - 12 months		9		9	
Total trade receivables - related parties	3	23	3	23	
Trade receivables - unrelated parties					
Aged on the basis of due dates					
Not yet due	97,372	88,718	97,372	88,718	
Past due					
Up to 3 months	85,913	72,533	85,913	72,533	
3 - 6 months	6,746	18,332	6,746	18,332	
6 - 12 months	6,273	5,934	6,273	5,934	
Over 12 months	25,331	32,084	25,331	32,084	
Total trade receivables - unrelated parties	221,635	217,601	221,635	217,601	
Less: Allowance for expected credit losses	(17,338)	(13,152)	(17,338)	(13,152)	
Total trade receivables - unrelated parties					
- net	204,297	204,449	204,297	204,449	
Total trade receivables - net	204,300	204,472	204,300	204,472	
Other receivables					
Other receivables - unrelated parties	6,942	5,654	6,759	5,473	
Accrued interest income	2,890	1,764	2,890	1,764	
Total other receivables	9,832	7,418	9,649	7,237	
Total trade and other receivables - net	214,132	211,890	213,949	211,709	

5. Other current financial assets

As at 30 April 2024 and 31 July 2023, other current financial assets consisted of the following:

(Unit: Thousand Baht)

Consolidated and separate financial statements				
Other current		Intere	Interest rate	
financial assets		(percent per annum		
30 April	31 July	30 April	31 July	
2024	2023	2024	2023	
271,508	140,000	1.00 - 2.20	1.00 - 2.00	
271,508	140,000	<u>=</u>		
	Other of financial 30 April 2024 271,508	Other current financial assets 30 April 31 July 2024 2023 271,508 140,000	Other current Interest financial assets (percent percent percen	

6. Investment in subsidiary

Details of investments in subsidiary as presented in the separate financial statements are as follows:

(Unit: Thousand Baht)

	Туре					
Company's name	of relation	30 April 31 July 2024 2023 (%) (%)	g percentage	Co	ost	
		30 April	31 July	30 April	31 July	
		2024	2023	2024	2023	
		(%)	(%)			
Local subsidiary						
Jatu Charoen Development	Direct holding					
Company Limited		99.97	99.97	1,000	1,000	

On 13 December 2021, the Board of Directors' meeting No. 5/2021 resolved to approve the establishment of a new subsidiary, Jatu Charoen Development Company Limited, which is engaged in health establishment and hotel business, providing elderly and dependency care both onsite and offsite as well as distributions of medicines, supplement products, medical supplies and equipments. The subsidiary has a registered capital of 10,000 shares with a par value of Baht 100 per share, totaling Baht 1 million. The subsidiary registered the establishment with the Department of Business Development, the Ministry of Commerce on 18 February 2022.

7. Property, plant and equipment

Movements in the property, plant and equipment account during the nine-month period ended 30 April 2024 are summarised below.

	(Unit: Thousand Ba		
	Consolidated	Separate	
	financial	financial	
	statements	statements	
Net book value as at 1 August 2023	894,272	894,272	
Additions during the period - at cost	124,483	124,449	
Disposals during the period - net book value at disposal date	(389)	(389)	
Depreciation for the period	(73,472)	(73,472)	
Net book value as at 30 April 2024	944,894	944,860	

8. Right-of-use assets

Movements in the Right-of-use assets account during the nine-month period ended 30 April 2024 are summarised below.

Thousand Baht)
Consolidated
and separate
financial
statements
569,657
(16,907)
552,750

The Company entered into a long-term lease agreement for lease of land and building which are the current operation hospital building with Thai Red Cross Society. The agreement is for a period of 30 years, from 9 November 2018 to 8 November 2048 with the lease payment of Baht 668 million, being payable in full upon signing the new lease agreement. The Company paid the lease payment of Baht 668 million to the Thai Red Cross Society on 22 February 2019.

9. Trade and other payables

(Unit: Thousand Baht) Consolidated Separate financial statements financial statements 30 April 31 July 30 April 31 July 2024 2023 2024 2023 Trade payables - unrelated parties 104,801 101,985 104,765 101,985 Other payables - unrelated parties 16,664 18,505 16,664 18,505 Accounts payable - construction 27,210 and equipment purchases 16,290 27,210 16,290 Accrued expenses 43,180 37,374 43,091 37,224 180,935 185,074 180,810 184,924 Total trade and other payables

10. Income tax

Interim corporate income tax is calculated on profit before income tax for the period, using the estimated effective tax rate for the year.

Income tax expenses for the three-month and nine-month periods ended 30 April 2024 and 2023 are made up follows:

(Unit: Thousand Baht)

	For three-month periods ended 30 April			
	Consoli	dated	Separ	rate
	financial st	atements	financial sta	atements
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>
Current income tax:				
Interim corporate income tax charge	21,819	17,716	21,819	17,715
Deferred tax:				
Relating to origination and reversal				
of temporary differences	(916)	519	(916)	519
Income tax expenses reported in				
the statements of comprehensive				
income	20,903	18,235	20,903	18,234

(Unit: Thousand Baht)

_	For nine-month periods ended 30 April				
	Consol	idated	Separate		
_	financial st	atements	financial sta	atements	
	<u>2024</u>	<u>2023</u>	<u>2024</u>	<u>2023</u>	
Current income tax:					
Interim corporate income tax charge	80,780	59,142	80,780	59,133	
Deferred tax:					
Relating to origination and reversal					
of temporary differences	(2,698)	(3,204)	(2,698)	(3,204)	
Income tax expenses reported in					
the statements of comprehensive					
income	78,082	55,938	78,082	55,929	

11. Dividends

		Total	Dividend
Dividends	Approved by	dividends	per share
		(Million Baht)	(Baht)
Final dividends for 2022	Annual General Meeting		
	of the shareholders on		
	17 November 2022	108.0	0.60
Total dividends for 2023		108.0	
Final dividends for 2023	Annual General Meeting		
	of the shareholders on		
	22 November 2023	108.0	0.60
Total dividends for 2024		108.0	

12. Operating segment information

Operating segment information is reported in a manner consistent with the internal reporting the chief operating decision maker has received and regularly reviewed to make decisions about resources to be allocated to the segment and assess its performance. The chief operating decision maker has been identified as Executive Committee.

The one main reportable operating segment of the Company is the hospital business and the single geographical area of its operation is Thailand. Segment performance is evaluated based on operating profit or loss and is measured consistently with operating profit or loss in the financial statements. As a result, all of the revenues, operating profits and assets as reflected in these financial statements pertain to the aforementioned reportable operating segment and geographical area.

13. Commitments and contingent liabilities

13.1 Commitments under service agreements

The Company had total minimum payments to be paid in the future under the service agreements as follows:

		(Unit: Million Baht)
	30 April 2024	31 July 2023
Payable:		
In up to 1 year	13.3	11.0
In over 1 year and up to 3 years	0.7	1.2

13.2 Capital commitments

As at 30 April 2024, the Company had capital commitments of Baht 146.6 million (31 July 2023: Baht 24.9 million) in respect of the acquisitions of buildings and building improvements, medical equipment and facility systems.

13.3 Guarantees

- a. As at 30 April 2024, the Company had credit facilities with a commercial bank for overdrafts of Baht 20 million and short-term loans of Baht 10 million (31 July 2023: Credit facilities with a commercial bank for overdrafts of Baht 20 million and short-term loans of Baht 10 million).
- b. As at 30 April 2024, the Company had outstanding bank guarantees of approximately Baht 6.4 million issued by the bank on behalf of the Company in respect of electricity use as required in the normal course of business. (31 July 2023: Baht 6.4 million).

14. Approval of interim financial statements

These interim financial statements were authorised for issue by the Company's Board of Directors on 12 June 2024.